SCHEMBL3915700

SCHEMBL3915700

CCCCCCCCCCCCCCC(I)C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 2/20 0.47
ADH1C P00326 2/20 0.47
ADH1A P07327 2/20 0.47
ADH4 P08319 2/20 0.47
ADH7 P40394 2/20 0.47
TSHR P16473 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 2/20 0.41
TRPA1 O75762 1/20 0.41
DDAH1 O94760 1/20 0.41
GAPDH P04406 1/20 0.41
GPR84 Q9NQS5 3/20 0.40
FDPS P14324 3/20 0.40
FFAR1 O14842 1/20 0.40
EPHX1 P07099 1/20 0.39
LMNA P02545 1/20 0.39
LCK P06239 1/20 0.39
PPARD Q03181 1/20 0.39
ZDHHC20 Q5W0Z9 1/20 0.39
ZDHHC2 Q9UIJ5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29380868 1.00 ADH1B (0.47) ADH1BADH1CADH1AADH4ADH7
SCHEMBL29380140 1.00 ADH1B (0.47) ADH1BADH1CADH1AADH4ADH7
SCHEMBL29380352 1.00 ADH1B (0.47) ADH1BADH1CADH1AADH4ADH7
SCHEMBL11144441 0.98
SCHEMBL28553161 0.90
SCHEMBL14601128 0.84 TSHR (0.31) TSHRSMN1; SMN2
SCHEMBL5326446 0.79
SCHEMBL7871168 0.78 GPR84 (0.41) ADH1BADH1CADH1AADH4ADH7
SCHEMBL7863831 0.78 GPR84 (0.41) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17879364 0.76 TSHR (0.50) TSHRMAPTGPR84FDPSFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2019964-A2 METHODS AND COMPOUNDS TO MODULATE PARVOVIRUS TRANSDUCTION OF MAMMALIAN CELLS OR TO ALTER VIRUS INFECTION. METHOD TO IDENTIFY A VIRAL RECEPTOR OR CO-RECEPTOR University of Iowa Research Foundation (US) 2009-02-04 EP disclosed
US-20090017062-A1 Methods and compounds to alter virus infection IOWA RESEARCH FOUNDATION IOWA CENTERS FOR ENTERPRI (US) 2009-01-15 US disclosed
US-20080261201-A1 Methods and compounds to alter virus infection UNIVERSITY OF IOWA RESEARCH FOUNDATION IOWA CENTERS FOR ENTERPRISE (US) 2008-10-23 US disclosed
WO-2007127464-A2 METHODS AND COMPOUNDS TO MODULATE PARVOVIRUS TRANSDUCTION OF MAMMALIAN CELLS OR TO ALTER VIRUS INFECTION, METHOD TO IDENTIFY A VIRAL RECEPTOR OR CO-RECEPTOR UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2007-11-08 WO disclosed
US-20060008512-A1 Composition and methods for improved animal performance HOOGE DANNY M 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090017062-A1 Methods and compounds to alter virus infection CYBB, NOX4, NOX5 ADH1B 65/4885ADH1C 1330/4885ADH1A 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.